Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ANVS Stock Forecast 2026-2027
$1.79
Current Price
$80.40M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ANVS Price Targets
+849.7%
To High Target of $17.00
+598.3%
To Median Target of $12.50
+346.9%
To Low Target of $8.00
ANVS Price Momentum
-3.8%
1 Week Change
-21.5%
1 Month Change
-41.5%
1 Year Change
-48.3%
Year-to-Date Change
-67.5%
From 52W High of $5.50
+16.2%
From 52W Low of $1.54
📊 TOP ANALYST CALLS
Did ANVS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Annovis Bio is one of their latest high-conviction picks.
Latest ANVS Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, ANVS has a bullish consensus with a median price target of $12.50 (ranging from $8.00 to $17.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $1.79, the median forecast implies a 598.3% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Sumant Kulkarni at Canaccord Genuity, projecting a 849.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANVS Analyst Ratings
2
Buy
0
Hold
0
Sell
ANVS Price Target Range
Low
$8.00
Average
$12.50
High
$17.00
Current: $1.79
Latest ANVS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANVS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 14, 2026 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $17.00 |
| Sep 30, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Sep 3, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jun 9, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 15, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Feb 10, 2025 | D. Boral Capital | Hold | Downgrade | $N/A | |
| Nov 11, 2024 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 11, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 25, 2024 | Maxim Group | Buy | Upgrade | $N/A | |
| Oct 16, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $30.00 |
| Oct 15, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $21.00 |
| Oct 1, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $30.00 |
| Aug 15, 2024 | EF Hutton | Buy | Maintains | $N/A | |
| Aug 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 13, 2024 | EF Hutton | Buy | Initiates | $N/A | |
| Jul 17, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 11, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jul 2, 2024 | Rodman & Renshaw | Buy | Reiterates | $N/A | |
| Jun 12, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 4, 2024 | Rodman & Renshaw | Buy | Initiates | $N/A |
Annovis Bio, Inc. (ANVS) Competitors
The following stocks are similar to Annovis Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Annovis Bio, Inc. (ANVS) Financial Data
Annovis Bio, Inc. has a market capitalization of $80.40M with a P/E ratio of -1.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -220.6%.
Valuation Metrics
Market Cap
$80.40M
Enterprise Value
$34.06M
P/E Ratio
-1.3x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+38.5%
Current Ratio
5.8x
Debt/Equity
0.0x
ROE
-220.6%
ROA
-106.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Annovis Bio, Inc. (ANVS) Business Model
About Annovis Bio, Inc.
What They Do
Develops drugs for neurodegenerative diseases.
Business Model
Annovis Bio, Inc. operates within the biopharmaceutical sector, focusing on the development of novel therapies aimed at inhibiting neurotoxic protein buildup in diseases such as Alzheimer's and Parkinson's. The company generates revenue through the successful development and commercialization of its drug candidates, addressing a critical market need for effective treatments in neurodegenerative disorders.
Additional Information
Annovis Bio is engaged in groundbreaking biomedical research and is well-positioned to meet the growing global demand for innovative solutions in the healthcare market. The company’s focus on halting or reversing disease progression underscores its potential impact in the pharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
8
CEO
Dr. Maria L. Maccecchini Ph.D.
Country
United States
IPO Year
2020
Website
www.annovisbio.comAnnovis Bio, Inc. (ANVS) Latest News & Analysis
Latest News
Annovis Bio Regains NYSE Listing Compliance
13 days ago
Quick Summary
Annovis Bio, Inc. (NYSE: ANVS) has regained compliance with NYSE listing standards, as it develops the oral therapy buntanetap for Alzheimer's and Parkinson's diseases.
Why It Matters
Annovis Bio's compliance with NYSE standards signals financial stability, potentially boosting investor confidence and impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
19 days ago
Quick Summary
Annovis Bio, Inc. priced a public offering of 7.9 million shares and warrants for 7.1 million shares as it advances its Phase 3 therapy for Alzheimer's and Parkinson's diseases.
Why It Matters
The public offering indicates Annovis Bio is raising capital, which could impact share dilution and investor confidence. Successful funding may accelerate development of its therapies for neurodegenerative diseases.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
20 days ago
Quick Summary
Annovis Bio, Inc. plans to launch an underwritten public offering of common stock and warrants to fund its Phase 3 trials for buntanetap, targeting Alzheimer's and Parkinson's diseases.
Why It Matters
Annovis Bio's public offering may dilute existing shares, impacting stock value. Investors will watch for funding implications on its Alzheimer's and Parkinson's drug development.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Annovis Bio (NYSE: ANVS) reports 85% enrollment in Phase 3 AD trial, expected to complete by summer 2026. NDA for buntanetap anticipated in early 2027 for AD and 2028 for PD.
Why It Matters
Annovis Bio's advancing clinical trials and upcoming NDA submissions for buntanetap could significantly impact its stock value, reflecting investor confidence in potential market approvals for Alzheimer's and Parkinson's treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
1 month ago
Quick Summary
Annovis Bio, Inc. (NYSE: ANVS) is in Phase 3 trials for its oral therapy, buntanetap, targeting Alzheimer's and Parkinson's diseases, led by Dr. Maria Maccecchini.
Why It Matters
Annovis Bio's advancement in Phase 3 trials for buntanetap targeting Alzheimer's and Parkinson's can significantly impact its stock value and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Annovis Bio's drug, Buntanetap, has shown improved cognition in early Alzheimer's patients while reducing neurotoxic proteins. Phase 3 study is ongoing, with 80% patient enrollment completed.
Why It Matters
Positive Phase 2/3 results for Buntanetap in Alzheimer's patients suggest potential for significant market impact, enhancing Annovis Bio's valuation and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ANVS Stock
What is Annovis Bio, Inc.'s (ANVS) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Annovis Bio, Inc. (ANVS) has a median price target of $12.50. The highest price target is $17.00 and the lowest is $8.00.
Is ANVS stock a good investment in 2026?
According to current analyst ratings, ANVS has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.79. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ANVS stock?
Wall Street analysts predict ANVS stock could reach $12.50 in the next 12 months. This represents a 598.3% increase from the current price of $1.79. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Annovis Bio, Inc.'s business model?
Annovis Bio, Inc. operates within the biopharmaceutical sector, focusing on the development of novel therapies aimed at inhibiting neurotoxic protein buildup in diseases such as Alzheimer's and Parkinson's. The company generates revenue through the successful development and commercialization of its drug candidates, addressing a critical market need for effective treatments in neurodegenerative disorders.
What is the highest forecasted price for ANVS Annovis Bio, Inc.?
The highest price target for ANVS is $17.00 from Sumant Kulkarni at Canaccord Genuity, which represents a 849.7% increase from the current price of $1.79.
What is the lowest forecasted price for ANVS Annovis Bio, Inc.?
The lowest price target for ANVS is $8.00 from at , which represents a 346.9% increase from the current price of $1.79.
What is the overall ANVS consensus from analysts for Annovis Bio, Inc.?
The overall analyst consensus for ANVS is bullish. Out of 4 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.50.
How accurate are ANVS stock price projections?
Stock price projections, including those for Annovis Bio, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 2:08 AM UTC